Biological reactor retrofitting using CFD-ASM modelling

In recent years, the interest in modelling activated sludge (AS) systems by means of Computational Fluid Dynamics (CFD) techniques has significantly increased. This work shows a successful case study combining CFD hydrodynamics and biokinetic modelling. The hydrodynamics is analysed by using the Reynolds-averaged Navier-Stokes equation for incompressible non-Newtonian fluids and SST turbulence model. Biokinetics has been included in the CFD as transport equations with source and sink terms defined by the Activated Sludge Model n degrees 1 (ASM1). Furthermore, a strategy for reducing the computational cost while maintaining accuracy of the results of these calculations has been proposed. This strategy is based on a two-step solver configuration and the definition of a variable timestep scheme. The resulting CFD-ASM approach permits a proper evaluation of denitrification in the anoxic tanks as well as the reproduction of nitrate and readily biodegradable substrate distributions. To demonstrate the strength of the proposed CFD-ASM, it has been used to evaluate the operation of a full-scale AS system and optimize its performance through changes in the biological reactor anoxic zone. The original configuration has been retrofitted and modified after detecting intrinsic defects in the fluid behaviour within the tank. This study has been assessed by analysing hydrodynamics in detail and validating the simulation results with tracer tests and flow velocity measurements. Substantial variations on the Residence Time Distribution have been confirmed when modifying the internal elements of the tank configuration: the wall-bushing and the stirrer positioning. As a result of this work, an influential short circuiting was corrected improving hydrodynamics and increasing mean residence time, all favouring denitrification efficiency. Outcomes of this study show the benefit of CFD when applied to AS tanks

Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry

Aims The European Society of Cardiology (ESC) EURObservational Research Programme (EORP) Non-ST-segment elevation myocardial infarction (NSTEMI) Registry aims to identify international patterns in NSTEMI management in clinical practice and outcomes against the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without ST-segment-elevation. Methods and results Consecutively hospitalised adult NSTEMI patients (n = 3620) were enrolled between 11 March 2019 and 6 March 2021, and individual patient data prospectively collected at 287 centres in 59 participating countries during a two-week enrolment period per centre. The registry collected data relating to baseline characteristics, major outcomes (inhospital death, acute heart failure, cardiogenic shock, bleeding, stroke/transient ischaemic attack, and 30-day mortality) and guideline-recommended NSTEMI care interventions: electrocardiogram pre- or in-hospital, prehospitalization receipt of aspirin, echocardiography, coronary angiography, referral to cardiac rehabilitation, smoking cessation advice, dietary advice, and prescription on discharge of aspirin, P2Y12 inhibition, angiotensin converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB), beta-blocker, and statin. Conclusion The EORP NSTEMI Registry is an international, prospective registry of care and outcomes of patients treated for NSTEMI, which will provide unique insights into the contemporary management of hospitalised NSTEMI patients, compliance with ESC 2015 NSTEMI Guidelines, and identify potential barriers to optimal management of this common clinical presentation associated with significant morbidity and mortality